Non-alcoholic Steatohepatitis Registry Platform Study

Inclusion Criteria:

(1) Subjects must be between 18 and 75 years old when signing the informed consent form, and must have the ability to sign the consent form independently; (2) NASH patients who meet one of the following conditions:

1. Liver biopsy was performed within 24 months before enrollment, and the pathologicaldiagnosis was NASH and the fibrosis stage was F2 or above;

2. FibroScan-AST (FAST) score ≥ 0.30 within 24 months before enrollment;

3. There are any of the following evidences of fatty liver

4. Controlled attenuation parameter (CAP) > 285 dB/m within 24 months beforeenrollment;

5. Liver ultrasonography showed fatty liver within 24 months before enrollment;

6. Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF)examination within 24 months before enrollment showed liver fat fraction ≥ 5%;and any of the following evidence of liver fibrosis

7. Liver stiffness measurement (LSM) ≥ 7.5kPa by vibration-controlled transientelastography (VCTE) within 24 months before enrollment;

8. The elasticity value of magnetic resonance elastography (MRE) examinationwithin 24 months before enrollment is ≥2.93kPa;

9. If there is no liver biopsy and no liver elastography equipment is available inthe research center, FIB-4>1.3 (under 65 years old) or>2 (over 65 years old)within 3 months before enrollment.

Exclusion Criteria:

1. History of liver transplantation;

2. Patients with bleeding tendency or coagulation dysfunction (for example, bleedingtendency, such as hemophilia, suspected hemangioma or suspected hydatid infection);

3. Exclude liver diseases caused by the following causes: alcoholic steatohepatitis,drug-induced, viral or autoimmune hepatitis, primary hemochromatosis, α1-antitrypsindeficiency, hepatolenticular degeneration, hypothyroidism, inflammatory boweldisease, Cushing's syndrome, celiac disease, β lipoprotein deficiency, lipoatrophicdiabetes mellitus, Mauriac syndrome, hypopituitarism, hypogonadism, polycysticovarian syndrome;

4. Have a history of malignant tumors in the past 5 years, excluding malignant tumorsthat have been cured by the investigator's judgment;

5. Pregnant or lactating women.